

Four clinical-stage assets, one critical path

Three clinical readouts in the next fifteen months

Yaqrıt is a clinical-stage biotech advancing four phase 2/3 therapeutics for advanced liver disease, an area that has seen no new approved drugs in 15 years. Built on pioneering research from UCL Liver Failure Group targeting underlying mechanisms driving disease progression, Yaqrıt has 3 expected clinical readouts over the next 15 months, providing near-term valuation inflection points in a market with significant unmet need. Estimated combined commercial opportunity is over \$9B. \$26M equity raised to date and \$24M highly competitive non-dilutive grants

● ONE CRITICAL PATH: INFLAMMATION

YAQ001 Enterosorb In the gut Adsorbs endotoxins and resets the microbiome	YAQ002 Cytox In the blood Removes endotoxins, replaces dysfunctional albumin	YAQ005 Hepyx At the receptor Blocks TLR4, the immune sensor that triggers inflammation	YAQ006/7 Amalive At the toxin Scavenges ammonia, the driver of hepatic encephalopathy (HE)
---	--	--	--

● THE PIPELINE AND ITS UNMET NEED

	INDICATION	PHASE 1	PHASE 2	PHASE 3
YAQ006 OPA-IV	HE, in hospital	ODD & fast track US		
YAQ007 OPA-oral	HE, outpatient			
YAQ005 Anti-TLR4	ACLF, grades 1-2	Initiated		
YAQ001 Carbon beads	Decompensated cirrhosis, IBS			
YAQ002 Liver support	ACLF grades 2-3	1st generation CE mark 2nd generation in randomized registrational trial		

Hepatic Encephalopathy

~30-40% of cirrhosis patients
 >50% mortality within 12 months

Acute-on-chronic liver failure

26% of US decompensated-cirrhosis admissions
 >50% dead within 90 days

● MULTIPLE NEAR-TERM MILESTONES

H2 2026 YAQ001 Phase 2a readout in PSC (primary sclerosing cholangitis)	H2 2026 YAQ006 Pivotal phase 3 initiation	H2 2027 YAQ002 * Registrational readout (2 nd generation)	H2 2027 YAQ005 Phase 2 data readout
---	---	--	---

● WHY NOW · IMPROVING COMEPETITIVE DYNAMICS IN LEAD INDICATION, HE

Nov 2024 ANTIMICROBIAL RESISTANCE Nature paper highlighted treatment for HE recurrence, rifaximin, causes resistance to last resort antibiotic	Jan 2026 PRIMARY PREVENTION FAILURE Bausch's two phase 3s for rifaximin in HE prevention failed to meet primary endpoint. No approved treatment today	Mar 2026 AMMONIA ROLE RECOGNIZED International Delphi consensus recognized ammonia's clinical significance in HE. Yet no ammonia scavengers are approved in HE
--	---	--

● INVESTMENT OPPORTUNITY · SERIES A UP TO \$70M

Up to \$70M at the corporate level or in individual assets via wholly-owned subsidiaries, Amalive, Hepyx and Enterosorb. Milestones fall 12-36 months after each investment. Yaqrıt will actively explore partnerships, out-licensing or public listing to crystallize value. Comparable liver asset transactions have each raised \$40-60M upfront, with milestones ranging up to \$350M (Bausch Health/DURECT; GENFIT/Versantis; Mallinckrodt/Ocera)

Contact: Troels Jordansen, CEO · Troels@Yaqrıt.com · +31 6 1834 5326

● LEAD FRANCHISE · AMMONIA · AMALIVE

L-ornithine phenylacetate (OPA): First-in-class ammonia scavenger reduces ammonia, a key underlying driver of hepatic encephalopathy (HE). Patent protection to 2044. Invented in UCL Liver Failure Group, acquired by Mallinckrodt for \$42M + \$75M contingent milestones in 2017, acquired by Yaqrit in Mallinckrodt bankruptcy

YAQ006 OPA intravenous Treatment of overt HE in hospital Status Phase 3-ready, protocol FDA-aligned. US orphan drug designation and fast track Ask \$45M to fund the pivotal phase 3 Basis New phase 3 design has >85% modelled probability of success, addressing critical issues identified in phase 2b clinical design. Phase 2b showed significant dose-dependent ammonia reduction and trend to clinical improvement	YAQ007 OPA oral Prevention of first and recurrent overt HE Status Adaptive phase 2b/3 in design Ask \$15M to fund phase 2b/3 Basis Phase 2a (Hepatology 2026) showed dose dependent ammonia reduction in HE patients. Ammonia scavenger class validated by prior phase 2 study with glycerol phenylbutyrate which cut HE events from 32% to 10%. No treatment approved today for primary prevention
--	---

● THE REST OF THE PIPELINE

YAQ005 Hepyx IP to 2039	TLR4 antagonist for acute-on-chronic liver failure (grade 1 and 2) Status Phase 2a A-TANGO trial ongoing, largely funded by EU Horizon 2020; 1st data H2-27 Ask \$3M to complete the trial to phase 2b readiness and FDA alignment Basis Reduces organ and systemic inflammation. Full safety package acquired from big pharma after phase 3 failure in sepsis. Mechanism in ACLF established in Yaqrit/UCL work (J.Hepatol. 2020; Sci Adv. 2024)
YAQ001 Enterosorb IP to 2046	Gut-restricted carbon adsorbent (FDA regulates as drug; EU as medical device) Status PSC (rare disease) UK study ongoing with readout H2 2026 Ask \$7M for CE mark in Europe; US FDA alignment; completion of 3 targeted trials to provide data for it to be considered a microbiome therapeutic platform Basis Adsorbs endotoxins and resets microbiome. Safety and tolerability established in cirrhosis (Gut 2024) with supporting microbiome and inflammation data
YAQ002 Cytos Life Sciences IP to 2044	DIALIVE liver support device Status 1st gen CE mark; 2nd gen in randomized registrational trial ALIVER readout H2-27 Ask \$2.5M to complete EU registration study together with grant award Basis Removes endotoxins and replaces dysfunctional albumin. Trial with 1st gen device (J.Hepatol 2023) met its safety primary and significantly shortened time to ACLF resolution and improvement in CLIF-C organ failure

Clinical program funded to date by EU Horizon 2020: 733057 ([ALIVER](#)) and 945096 ([A-TANGO](#)) and NIHR Invention for Innovation award NIHR206537

● LEADERSHIP



Professor Rajiv Jalan, MD, Ph.D.
Chair, Founder, CMO/CSO

Professor of Hepatology at UCL & Consultant Hepatologist at the Royal Free London. First to identify ACLF as a distinct entity; inventor of OPA and YAQ001. ~590 peer-reviewed papers (H-index: 124). Former Scientific Director, EF CLIF; former Editor-in-Chief, J. Hepatol.



Troels Jordansen
Chief Executive Officer, Board Member

35+ years in commercial & senior leadership in life sciences, including IsoTis, Genzyme and J&J Orthopaedics. Founding Partner, Altius Bioventures. Ex-CEO Glycostem Therapeutics and Check4Cancer. Two IPOs, multiple licensing deals, and public listed board work

Board Rajiv Jalan (Chair) · Troels Jordansen · Tauhid Ali, Ph.D. · Ronen Israel

Management Julie Bailey, CFO · Timothy Jenkins, Ph.D., CDO · Amrik Shah, ScD, Chief Biomedical Officer · Karen Church, Ph.D., Head of Regulatory Affairs (FDA), QA & Clinical Ops · Carrie Morgan, SVP Clinical Ops · Jan Bart, Ph.D., Clinical, Regulatory (European) & Quality Management · Michal Kowalski, SVP Operations · Darren Rubin, VP Innovation Strategy · Mary-Ann Chang, CFA, SVP Comms & Strategy